Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication.
INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury.
In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials.
Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.
Company Details
- Employees
- 11
- Address
- 1275 Kinnear Rd, Columbus,ohio 43212,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://invirsa.com
- HQ
- Columbus, Ohio
Invirsa, Inc Questions
Invirsa, Inc's website is http://invirsa.com
Invirsa, Inc's LinkedIn profile is https://www.linkedin.com/company/invirsa
Invirsa, Inc has
11 employees.
View email and phone details for 11
employees at Invirsa, Inc.
Invirsa, Inc's industry is
Pharmaceutical Manufacturing
Invirsa, Inc's categories are Pharmaceutical Manufacturing
